31st Oct 2018 10:30
LONDON (Alliance News) - hVIVO PLC said Wednesday preliminary results from the first in-man study of AGS-v, a proposed mosquito-borne disease vaccine, met primary objectives and endpoints regarding safety and humoral response.
Shares in the clinical development services company were trading down 9.3% at 39.00 pence each on Wednesday.
The results from the double-blind, placebo-controlled phase one trial showed AGS-v did not cause significant adverse events.
The company added the remaining primary and secondary endpoints will be evaluated once the full and data from the trial are available.
"Given favourable safety profile and results so far, the vaccine warrants further development," hVIVO added.
AGS-v is being developed by Imutex Ltd, hVIVO's 49% joint venture with SEEK Group.
hVIVO Executive Chairman Trevor Phillips said: "The presentation of these partial preliminary results by NIH is encouraging regarding safety and immunogenicity responses.
"We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible."
Related Shares:
hVIVO